Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
Oral vancomycin and oral metronidazole have several limitations with regard to their use in the treatment of Clostridium difficile infections (CDIs); however, oral vancomycin has been considered the gold standard in clinical trials. In June 2012, fidaxomicin received Health Canada approval for the t...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Pulsus Group Inc
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692299/ |